PIVKA—Ⅱ与GP73联合检测在AFP低浓度肝癌诊断中的临床价值
2018-04-25何彪邱振华黄燕金苏晓文
何彪 邱振华 黄燕金 苏晓文
【摘要】 目的:探讨异常凝血酶原(protein induced by vitamin K absence or antagonist-Ⅱ,PIVKA-Ⅱ)与高尔基体蛋白(Golgi glycoprotein,GP73)联合检测对诊断血清甲胎蛋白(alpha-fetoprotein,AFP)低浓度的原发性肝癌(primary hepatic carcinoma,PHC)的临床价值。方法:选取本院2015年3月-2016年12月AFP低浓度PHC72例,其他肝病68例,同期体检正常对照组110例,分别检测PIVKA-Ⅱ(ELISA)和GP73(ELISA)、AFP(化学发光法)的血清浓度水平。结果:PIVKA-Ⅱ与GP73联合检测在AFP低浓度PHC的系列试验特异度高达100%,联合试验敏感度达90.2%。结论:单独检测PIVKA-Ⅱ和GP73对AFP低浓度肝癌具有较高的诊断价值,PIVKA-Ⅱ与GP73联合检测可提高AFP低浓度肝癌诊断。
【关键词】 肝癌; PIVKA-II; GP73; AFP
【Abstract】 Objective:To combined detection of PIVKA-Ⅱ and GP73 for the diagnosis of low concentration of AFP PHC clinical value.Method:72 cases of low concentration of AFP PHC,and other liver diseases of 58 cases were selected in our hospital from May 2015 to December 2016,110 cases of normal control group in the same physical examination,they were detected in PIVKA-Ⅱ(ELISA)and GP73 (ELISA),AFP(chemiluminescence)concentration level.Result:Combined detection of PIVKA-Ⅱ and GP73 had high diagnostic efficacy at low AFP concentration in PHC,and the specificity of the test was as high as 100%.Joint test sensitivity was 90.2%.Conclusion:The independent detection of PIVKA-Ⅱ and GP73 is high diagnostic value for low AFP PHC,and the combined detection of PIVKA-II and GP73 can improve the diagnostic value of low AFP PHC.
【Key words】 Liver cancer; PIVKA-Ⅱ; GP73; AFP
First-authors address:The Peoples Hospital of Gaozhou,Gaozhou 525200,China
doi:10.3969/j.issn.1674-4985.2018.04.028
原发性肝癌(primary hepatic carcinoma,PHC)是现今我国第4位的常见恶性肿瘤,严重威胁我国人民的生命和健康[1-2]。对肝癌高危人群的筛查,有助于早期发现、早期诊断、早期治疗,是提高肝癌疗效的关键。临床上把早期的诊疗作为延长PHC患者生存期和改善生活质量的重要策略。血清甲胎蛋白(alpha-fetoprotein,AFP)是目前大多数医院最常用的PHC肿瘤标志物,但灵敏度和特异性都不能满足临床需要,约30%的肝癌患者AFP水平正常[3]。人异常凝血酶原(protein induced by vitamin K absence or antagonist-II,PIVKA-Ⅱ)是肝脏合成的异常脱羧基凝血酶原,最近研究表示它能通过诱导和刺激肝癌细胞的增殖和侵袭。多项研究数据表明高尔基体蛋白(Golgi glycoprotein,GP73)在肝癌患者中有高浓度的表达,具有较高的特异性。本研究拟通过对PIVKA-Ⅱ与GP73浓度水平回顾性的分析,以提高在AFP低浓度的PHC实验室诊断水平,现报道如下。
1 资料与方法
1.1 一般资料 选取本院2015年3月-2016年12月的肝病患者140例,纳入标准:严格按照《原发性肝癌诊疗规范》(2017年版)进行筛选。排除标准:其他恶性肿瘤患者;……
